Benfotiamine
Benfotiamine (Fat-Soluble Vitamin B1)
Fat-soluble form of vitamin B1 with superior absorption that protects against glycation and supports nerve health.
Benfotiamine is a synthetic, fat-soluble derivative of thiamine (B1) with 5x greater bioavailability. It reduces advanced glycation end-products (AGEs) that damage nerves and blood vessels in diabetes. Used clinically for diabetic neuropathy and increasingly for anyone concerned about blood sugar, nerve health, or alcohol-related B1 depletion.
Mechanisms of Action
AGE Inhibition
Blocks formation of damaging glycation products
Nerve Protection
Protects nerve cells from glucose damage
Recommended Dose
150-600mg daily
Optimal Timing
- With meals
Take with food
Best Form
Benfotiamine capsules
Alternatives: Combined with other B vitamins
Often combined with alpha-lipoic acid for enhanced neuropathy support.
Duration
Minimum: 6 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Fat-soluble — take with food containing fat for best absorption.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Neuropathy Relief
Reduced numbness, tingling, pain
AGE Reduction
Lower glycation markers
Commonly used; may help with neuropathy
Who Should NOT Take This
- Known allergy or hypersensitivity to Benfotiamine or related compounds
Drug Interactions
Thiamine may interfere with this cancer drug
Possible Side Effects
Tip: Take with food
Top studies from 40+ peer-reviewed papers
Raval AD et al. • The Cochrane database of systematic reviews (2015)
“There is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying progression of DKD.”
Key Findings:
- There is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying progression of DKD.
- Thiamine was found to be beneficial for reduction in albuminuria in a single study; however, there was lack of any improvement in kidney function or blood pressure following the use of vitamin B preparations used alone or in combination.
- These findings require further confirmation given the limitations of the small number and poor quality of the available studies.
Muley A et al. • BMJ open (2022)
“Benfotiamine reduced triglyceride level (MD, -1.10; 95% CI: -1.90 to -0.30) in 120 mg/day dose as compared with placebo 150 mg/day, however this was not demonstrated in higher doses.”
Key Findings:
- There was a significant increase in high-density lipoprotein (HDL) (MD, 0.10; 95% CI: 0.10 to 0.20) at 3-month follow-up.
- Benfotiamine reduced triglyceride level (MD, -1.10; 95% CI: -1.90 to -0.30) in 120 mg/day dose as compared with placebo 150 mg/day, however this was not demonstrated in higher doses.
- Further research warranted to confirm findings
Raj V et al. • European review for medical and pharmacological sciences (2018)
“In the present review, we have comprehensively reviewed all the molecular targets modulated by BFT to provide mechanistic perspective to highlight its pleiotropic effects.”
Key Findings:
- The reduction in AGEs subsequently decreases metabolic stress which benefits vascular complications seen in diabetes.
- The effects of BFT on the AGE-dependent pathway is well established.
- In the present review, we have comprehensively reviewed all the molecular targets modulated by BFT to provide mechanistic perspective to highlight its pleiotropic effects.
Ang CD et al. • The Cochrane database of systematic reviews (2008)
“There are only limited data in randomised trials testing the efficacy of vitamin B for treating peripheral neuropathy and the evidence is insufficient to determine whether vitamin B is beneficial or harmful.”
Key Findings:
- There are only limited data in randomised trials testing the efficacy of vitamin B for treating peripheral neuropathy and the evidence is insufficient to determine whether vitamin B is beneficial or harmful.
- One small trial in alcoholic peripheral neuropathy reported slightly greater improvement in vibration perception threshold with oral benfotiamine for eight weeks than placebo.
- In another small study, a higher dose of oral vitamin B complex for four weeks was more efficacious than a lower dose in reducing symptoms and signs.
- Vitamin B administered by various routes for two to eight weeks was less efficacious than alpha-lipoic acid, cilostazol or cytidine triphosphate in short-term improvement of clinical and nerve conduction study outcomes.
Hammes HP et al. • Nature Medicine (2003)
“Benfotiamine prevented microvascular damage through AGE inhibition.”
Key Findings:
- Blocked AGE formation
- Protected microvasculature
- Mechanism established
Study Type Distribution
Goals This Supplement Supports
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.